← The Wire
KYTXNasdaq
Kyverna Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · DE · CIK 1994702
Kyverna Therapeutics develops cell therapies for autoimmune diseases, including its CAR T-cell product candidate KYV-101
red 8-K · 90d
$490M
Market cap
$8.78
Last close
+4.0%
1D
+5.8%
5D
1.4M
Volume
Price · last 39 sessions-2.4%
May 4L $7.47 · H $10.78Jun 29
64
Total filings
Jun 2, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 2, 20268-KExecutive Change · Company UpdateMay 18, 202610-Q10-QMay 12, 20268-KResults of OperationsMay 12, 20268-KCompany UpdateMay 4, 20268-KReg FD DisclosureApr 22, 20268-KReg FD DisclosureApr 22, 20268-KReg FD DisclosureApr 20, 2026DEFA14ADEFA14AApr 13, 2026DEF 14ADEF 14AApr 13, 2026424B5424B5Apr 2, 202610-K10-KMar 26, 20268-KResults of OperationsMar 26, 20268-KExecutive Change · Company UpdateFeb 24, 20268-KExecutive Change · Company UpdateFeb 3, 20268-KExecutive Change · Results of OperationsJan 12, 20268-KMaterial Agreement · Company UpdateDec 18, 2025424B5PROSPECTUS SUPPLEMENTDec 18, 2025424B5PROSPECTUS SUPPLEMENTDec 15, 20258-KReg FD DisclosureDec 15, 20258-KReg FD DisclosureDec 15, 202510-Q10-QNov 12, 20258-KResults of OperationsNov 12, 20258-KMaterial Agreement · New Debt / ObligationNov 3, 20258-KReg FD DisclosureOct 29, 20258-KReg FD DisclosureOct 29, 20258-KExecutive ChangeSep 25, 202510-Q10-QAug 12, 20258-KResults of OperationsAug 12, 20258-KExecutive Change · Company UpdateJun 30, 20258-KShareholder VoteJun 3, 202510-Q10-QMay 13, 20258-KResults of OperationsMay 13, 2025424B5424B5Apr 15, 2025DEFA14ADEFA14AApr 14, 2025DEF 14ADEF 14AApr 14, 20258-KMaterial AgreementMar 27, 202510-K10-KMar 27, 20258-KResults of OperationsMar 27, 20258-KCompany UpdateJan 21, 20258-KReg FD DisclosureJan 13, 20258-KExecutive ChangeNov 26, 202410-Q10-QNov 13, 20248-KExecutive Change · Results of OperationsNov 13, 2024SC 13GSC 13GNov 12, 20248-KExecutive Change · Company UpdateOct 21, 2024SC 13GFILING KYVERNA THERAPEUTICS, INC.Oct 10, 20248-KExecutive Change · Company UpdateSep 16, 202410-Q10-QAug 12, 20248-KResults of OperationsAug 12, 20248-KReg FD Disclosure · Company UpdateJul 15, 20248-KReg FD DisclosureJun 14, 202410-Q10-QMay 14, 20248-KResults of OperationsMay 14, 2024SC 13DSCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIPMay 3, 202410-K10-KMar 26, 20248-KResults of OperationsMar 26, 2024SC 13GSC 13GFeb 22, 2024SC 13GSC 13GFeb 14, 20248-KBylaw Amendment · Company UpdateFeb 12, 2024424B4424B4Feb 8, 2024S-1/AS-1/AFeb 6, 2024S-1/AS-1/AFeb 1, 2024S-1S-1Jan 16, 2024
Insider Activity
◆ Cluster Buy · 2 insidersIn the 90 days to Dec 18, 2025: 2 insiders bought $2.0M · 1 sold $293K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 18, 2025 | Seidenberg Beth CDirector | Buy | 133,333 | $7.50 | $1000K |
| Dec 18, 2025 | Westlake Biopartners Opportunity Fund I, L.P.TenPercentOwner | Buy | 133,333 | $7.50 | $1000K |
| Dec 15, 2025 | Walker Karen MarieChief Technology Officer | Sell | 23,998 | $12.20 | $293K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance